Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3917-3919

  Chau, Andrew S ^a   Chen, Guodong ^a   McNicholas, Paul M ^a   Mann, Paul A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE;

ABSIDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ENZYME SYNTHESIS; FUNGAL GENE; GENE EXPRESSION; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHIZOPUS ORYZAE; SACCHAROMYCES CEREVISIAE; STEROL SYNTHESIS;

ABSIDIA; AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ERGOSTEROL; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; RHIZOPUS; SACCHAROMYCES CEREVISIAE; TRIAZOLES;

EID: 33750581779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00747-06     Document Type: Article

References (16)

1. Ballard, S. A., S. L. Kelly, S. W. Ellis, and P. F. Troke. 1990. Interaction of microsomal cytochrome P-450 isolated from Aspergillus fumigatus with fluconazole and itraconazole. J. Med. Vet. Mycol. 28:327-334.
2. Calabrese, D., J. Bille, and D. Sanglard. 2000. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146:2743-2754.
3. Chau, A. S., C. A. Mendrick, F. J. Sabatelli, D. Loebenberg, and P. M. McNicholas. 2004. Application of real-time quantitative PCR to the molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents Chemother. 48:2124-2131.
4. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. National Committee for Laboratory Standards, Wayne, Pa.
5. Goldman, G. H., M. E. da Silva Ferreiraqq, Edos Reis Marques, M. Savoldi, D. Perlin, S. Park, P. C. Godoy Martinez, M. H. Goldman, and A. L. Colombo. 2004. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn. Microbiol. Infect. Dis. 501:25-32.
6. Greenberg, R. N., K. Mullane, J. A. H. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
7. Herbrecht, R. 2004. Posaconazole: a potent extended-spectrum triazole and anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58:612-624.
8. Kelly, S. L., D. C. Lamb, and D. E. Kelly. 1999. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol. Lett. 180:171-175.
9. Kontoyiannis, D. P., M. S. Lionakis, R. E. Lewis, G. Chamilos, M. Healy, M. C. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. J. Walsh, and I.I. Raad. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191:1350-1360.
10. Kudo, M., M. Ohi, Y. Aoyama, Y. Nitahara, S. K. Chung, and Y. Yoshida. 2005. Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds. J. Biochem. 137:625-632.
11. Munayyer, H. K., P. A. Mann, A. S. Chau, T. Yarosh-Tomaine, J. R. Greene, R. S. Hare, L. Heimark, R. E. Palermo, D. Loebenberg, and P. M. McNicholas. 2004. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob. Agents Chemother. 48:3690-3696.
12. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 4:634-653.
13. Sabatelli, F., R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
14. Torres, H., R. Y. Hachem, R. F. Chemaly, D. P. Kontoyiannis, and I.I. Raad. 2005. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5:775-785.
15. van Burik, J. H., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:61-65.
16. Wheat, L. J., P. Connolly, M. Smedema, M. Durkin, E. Brizendine, P. Mann, R. Patel, P. M. McNicholas, and M. Goldman. 2006. Activity of newer triazoles against Histoplasma capsulation from patients with AIDS who failed fluconazole. J. Antimicrob. Chemother. 57:1235-1239.